1. Home
  2. ACU vs ACRS Comparison

ACU vs ACRS Comparison

Compare ACU & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACU
  • ACRS
  • Stock Information
  • Founded
  • ACU 1867
  • ACRS 2012
  • Country
  • ACU United States
  • ACRS United States
  • Employees
  • ACU N/A
  • ACRS N/A
  • Industry
  • ACU Industrial Machinery/Components
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACU Consumer Discretionary
  • ACRS Health Care
  • Exchange
  • ACU Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • ACU 151.5M
  • ACRS 127.6M
  • IPO Year
  • ACU N/A
  • ACRS 2015
  • Fundamental
  • Price
  • ACU $38.92
  • ACRS $1.22
  • Analyst Decision
  • ACU
  • ACRS Strong Buy
  • Analyst Count
  • ACU 0
  • ACRS 7
  • Target Price
  • ACU N/A
  • ACRS $10.67
  • AVG Volume (30 Days)
  • ACU 17.9K
  • ACRS 711.2K
  • Earning Date
  • ACU 04-17-2025
  • ACRS 05-08-2025
  • Dividend Yield
  • ACU 1.54%
  • ACRS N/A
  • EPS Growth
  • ACU N/A
  • ACRS N/A
  • EPS
  • ACU 2.48
  • ACRS N/A
  • Revenue
  • ACU $195,491,991.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • ACU $4.87
  • ACRS N/A
  • Revenue Next Year
  • ACU $3.65
  • ACRS $425.96
  • P/E Ratio
  • ACU $15.71
  • ACRS N/A
  • Revenue Growth
  • ACU 2.56
  • ACRS N/A
  • 52 Week Low
  • ACU $32.85
  • ACRS $0.95
  • 52 Week High
  • ACU $50.00
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • ACU 49.05
  • ACRS 40.99
  • Support Level
  • ACU $37.23
  • ACRS $1.20
  • Resistance Level
  • ACU $39.29
  • ACRS $1.38
  • Average True Range (ATR)
  • ACU 1.13
  • ACRS 0.11
  • MACD
  • ACU -0.17
  • ACRS 0.01
  • Stochastic Oscillator
  • ACU 32.39
  • ACRS 10.00

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: